TY  - CHAP
AU  - Seyma Katrinli
AU  - Kamil Ozdil
AU  - Gizem Dinler-Doganay
AU  - Levent
Doganay
ED  - Rodrigo Valenzuela
Y1  - 2017-12-20
PY  - 2017
T1  - Non-alcoholic Fatty Liver Disease: What We Learn from Omics Studies
N2  - Nonalcoholic fatty liver disease (NAFLD) with a prevalence of 20-30% worldwide is characterized by the buildup of fat in the liver (liver steatosis) with no or little alcohol consumption. Its principal causes are modern diet and occidental lifestyle. It is characterized by metabolic disturbances such as insulin resistance, inflammation, and oxidative stress, considered as the hepatic manifestation of metabolic syndrome. There is no effective drug therapy for this disease; therefore, lifestyle interventions remain as the first-line treatment. Nevertheless, the adherence rates to this type of treatment are very low, so great efforts are focused at finding novel therapeutic agents for the prevention of hepatic steatosis and its progression. This book presents a systematic and comprehensive revision about NAFLD, highlighting its epidemiological and molecular aspects, as well as its prevention and treatment.
BT  - Non-Alcoholic Fatty Liver Disease
SP  - Ch. 1
UR  - https://doi.org/10.5772/intechopen.71025
DO  - 10.5772/intechopen.71025
SN  - 978-953-51-3924-9
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-19
ER  -